











### CONCLUSION

Glucosamine sulfate could be considered a novel adjunctive immunomodulatory agent in management of OLP inducing more rapid initial response and lower rate of recurrence even with substandard dose of topical corticosteroid. More comparative randomized clinical trials with longer follow up periods are required to investigate clinical effect of combination between low dose of systemic corticosteroid and GlcN in severe cases of OLP and other mucocutaneous immune mediated diseases and to compare GlcN effect with other immunomodulatory agents as calcinurin inhibitors. Moreover, pharmacological preparation and testing of topical GlcN delivery system for oral use would be a future research era.

### ACKNOWLEDGEMENTS

We thank Department of Skin and Venereal disease staff, Faculty of Medicine, Ain Shams University for assisting in recruiting patients.

### CONFLICT OF INTEREST:

The authors declare that they have no conflicts of interest.

### REFERENCES

- [1] Gupta, S. Jawanda, M.K. Oral Lichen Planus: An Update on Etiology, Pathogenesis, Clinical Presentation, Diagnosis and Management. *Indian J Dermatol.* 2015, 60, 222–229.
- [2] Mollaoglu, N. Oral lichen planus: a review. *Br J Oral Maxillofac Surg.* 2000, 38, 370–377.
- [3] Sugerman, P.B., Savage, N.W., Walsh, L.J., Zhao, Z.Z., Zhou, X.J., Khan, A. The Pathogenesis of Oral Lichen Planus. *Crit Rev Oral Biol Med.* 2002, 13, 350–365.
- [4] Li, Q., Verma, I.M. NF-kappaB regulation in the immune system. *Nat Rev Immunol.* 2002, 2, 725–734.
- [5] Hansberger, M.W., Campbell, J.A., Danthi, P., Arrate, P., Pennington, K.N., Marcu, K.B. I kappa B kinase subunits alpha and gamma are required for activation of NF-kappaB and induction of apoptosis by mammalian reovirus. *J Virol.* 2007, 81, 1360–1371.
- [6] Ge, Y., Xu, Y., Sun, W., Man, Z., Zhu, L., Xia, X. The molecular mechanisms of the effect of Dexamethasone and Cyclosporin A on TLR4 /NF-κB signaling pathway activation in oral lichen planus. *Gene.* 2012, 508, 157–164.
- [7] Zhang, D., Wang, J., Li, Z., Zhou, M., Chen, Q., Zeng, X. The Activation of NF-κB in Infiltrated Mononuclear Cells Negatively Correlates with Treg Cell Frequency in Oral Lichen Planus. *Inflammation.* 2015, 38, 1683–1689.
- [8] Leung, D.Y.M., Bloom, J.W. Update on glucocorticoid action and resistance. *J Allergy Clin Immunol.* 2003, 111, 3–22.
- [9] Thongprasom, K., Dhanuthai, K. Steroids in the treatment of lichen planus: a review. *J Oral Sci.* 2008, 50, 377–385.
- [10] Thongprasom, K., Carrozzo, M., Furness, S., Lodi, G. Interventions for treating oral lichen planus. *Cochrane Database Syst Rev.* 2011:CD001168.
- [11] Distler, J., Anguelouch, A. Evidence-based practice: review of clinical evidence on the efficacy of glucosamine and chondroitin in the treatment of osteoarthritis. *J Am Acad Nurse Pract.* 2006, 18, 487–493.
- [12] Reginster, J.Y., Neuprez, A., Lecart, M.P., Sarlet, N., Bruyere, O. Role of glucosamine in the treatment for osteoarthritis. *Rheumatol Int.* 2012, 32, 2959–2967.
- [13] Kim, C.H., Choi, Y.S., Cheong, K.A., Lee, A.Y. Mechanism underlying the effect of combined therapy using glucosamine and low-dose cyclosporine A on the development of atopic dermatitis-like skin lesions in NC/Nga mice. *Int Immunopharmacol.* 2013, 15, 424–432.
- [14] Kim, C.H., Cheong, K.A., Park, C.D., Lee, A.Y. Therapeutic effects of combination using glucosamine plus tacrolimus (FK-506) on the development of atopic dermatitis-like skin lesions in NC/Nga mice. *Scand J Immunol.* 2012, 75, 471–478.
- [15] Thongprasom, K., Luengvisut, P., Wongwatanakij, A., Boonjatturus, C. Clinical evaluation in treatment of oral lichen planus with topical fluocinonone acetonide: A 2-year follow-up. *J Oral Pathol Med.* 2003, 32, 315–322.
- [16] Scott, J., Huskisson, E.C. Graphic representation of pain. *Pain.* 1976, 2, 175–184.
- [17] Jin, S.Y., Lim, W.S., Sung, N.H., Cheong, K.A., Lee, A.Y. Combination of glucosamine and low-dose cyclosporine for atopic dermatitis treatment: a randomized, placebo-controlled, double-blind, parallel clinical trial. *Dermatol Ther.* 2015, 28, 44–51.
- [18] Kwon, H.B., Ahn, B.J., Choi, Y., Jin, S.Y., Cheong, K.A., Lee, J. Combination of glucosamine improved therapeutic effect of low-dose cyclosporin A in patients with atopic dermatitis: A pilot study. *J Dermatol.* 2013, 40, 207–210.
- [19] Laeijendecker, R., Tank, B., Dekker, S.K., Neumann, H.A.M. A comparison of treatment of oral lichen planus with topical tacrolimus and triamcinolone acetonide ointment. *Acta Derm Venereol.* 2006, 86, 227–229.
- [20] Karatsaidis, A., Hayashi, K., Schreurs, O., Helgeland, K., Schenck, K. Survival signalling in keratinocytes of erythematous oral lichen planus. *J Oral Pathol Med.* 2007, 36, 215–222.
- [21] Zhou, G., Xia, K., Du, G., Chen, X., Xu, X., Lu, R. Activation of nuclear factor-kappa B correlates with tumor necrosis factor-alpha in oral lichen planus: A clinicopathologic study in atrophic-erosive and reticular form. *J Oral Pathol Med.* 2009, 38, 559–564.
- [22] Nottingham, L.K., Yan, C.H., Yang, X., Si, H., Coupar, J., Bian, Y. Aberrant IKKα and IKKβ cooperatively activate NF-κB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer. *Oncogene* 2014, 33, 1135–1147.
- [23] Mahmoud, M.M., Afifi, M.M. Anti-angiogenic therapy (bevacizumab) in the management of oral lichen planus. *Eur J Oral Sci.* 2016, 124, 119–126.